Alluvi, known as BI 4744, presents a significant development in obesity care. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive results in research studies, possibly outperforming available https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/